About PepGen Inc.

PepGen Inc. is an innovative biotechnology company founded in 2018 with a mission to transform the treatment of severe neuromuscular and neurologic diseases through its proprietary Enhanced Delivery Oligonucleotide (EDO) platform. The company's groundbreaking technology addresses a critical limitation in oligonucleotide therapeutics by improving cellular uptake and tissue penetration, potentially enabling more effective treatments for patients with limited options. PEPG stock price reflects investor confidence in the company's novel approach and the significant market opportunity for improved therapies in neuromuscular diseases.

The company is led by an accomplished team of biotechnology executives and scientific experts with proven track records in drug development and commercialization. CEO James McArthur, Ph.D., brings extensive experience from leadership roles at major pharmaceutical companies, while the scientific team includes pioneers in oligonucleotide chemistry and neuromuscular disease research. This combination of business acumen and scientific expertise has positioned PepGen to advance its pipeline efficiently, contributing to positive momentum in PEPG stock price as clinical programs progress.

PepGen's operations focus on developing and advancing a pipeline of EDO peptide-conjugated oligonucleotide candidates targeting severe genetic diseases including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). The company's lead programs have demonstrated promising preclinical results, showing improved delivery to target tissues compared to conventional approaches. With multiple clinical trials underway and a robust pipeline of additional candidates, PepGen represents an compelling investment opportunity in the high-growth rare disease therapeutics market, where successful treatments can command premium pricing and address significant unmet medical needs.